Strongbridge

SBBP NASDAQ
2.420
-0.120
-4.72%
After Hours: 2.420 0 0.00% 16:00 08/23 EDT
Open
2.520
Prev Close
2.540
High
2.580
Low
2.420
Volume
84.97K
Avg Vol (3M)
184.57K
52 Week High
6.52
52 Week Low
2.400
% Turnover
0.16%
Market Cap
131.13M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Strongbridge SBBP stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
MORE >

Recently

Name
Price
%Change